Flagship Pioneering’s Denali Therapeutics DNLI Stock Holding History

Flagship Pioneering’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,364,516	Closed	-$28M	–	7
2024 Q1	$28M	Sell	1,364,516 -955,452	-41%	-$18M	1.84%	5
2023 Q4	$49.8M	Sell	2,319,968 -300,000	-11%	-$5.94M	3.76%	5
2023 Q3	$54M	Hold	2,619,968	–	–	3.92%	6
2023 Q2	$77.3M	Hold	2,619,968	–	–	3.45%	6
2023 Q1	$60.4M	Hold	2,619,968	–	–	2.35%	6
2022 Q4	$72.9M	Hold	2,619,968	–	–	2.33%	7
2022 Q3	$80.4M	Hold	2,619,968	–	–	3.38%	7
2022 Q2	$77.1M	Hold	2,619,968	–	–	2.9%	6
2022 Q1	$84.3M	Hold	2,619,968	–	–	1.98%	7
2021 Q4	$117M	Sell	2,619,968 -110,295	-4%	-$5.23M	1.81%	8
2021 Q3	$138M	Hold	2,730,263	–	–	1.44%	7
2021 Q2	$214M	Hold	2,730,263	–	–	2.74%	6
2021 Q1	$156M	Hold	2,730,263	–	–	2.5%	9
2020 Q4	$229M	Sell	2,730,263 -3,250,000	-54%	-$196M	4.16%	7
2020 Q3	$214M	Sell	5,980,263 -2,000,000	-25%	-$60.2M	5.92%	4
2020 Q2	$193M	Hold	7,980,263	–	–	5.61%	3
2020 Q1	$140M	Hold	7,980,263	–	–	6.55%	3
2019 Q4	$139M	Sell	7,980,263 -25,484	-0.3%	-$424K	7.77%	3
2019 Q3	$123M	Hold	8,005,747	–	–	6.71%	4
2019 Q2	$166M	Hold	8,005,747	–	–	7.19%	4
2019 Q1	$186M	Sell	8,005,747 -913,002	-10%	-$19.1M	7.04%	4
2018 Q4	$184M	Hold	8,918,749	–	–	9%	4
2018 Q3	$194M	Hold	8,918,749	–	–	12.82%	3
2018 Q2	$136M	Hold	8,918,749	–	–	26.05%	2
2018 Q1	$176M	Hold	8,918,749	–	–	50.92%	1
2017 Q4	$139M	Buy	+8,918,749	New	+$160M	35.37%	1

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TPC

Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Flagship Pioneering's DNLI Position: Q2 2024 in Review

Flagship Pioneering sold out of Denali Therapeutics (DNLI) in Q2 2024, closing a stake of 1,364,516 shares — an estimated $28M sold.

Flagship Pioneering first reported a position in DNLI in Q4 2017 and held it in 26 quarters. The position peaked at $229M in Q4 2020. 203 funds tracked by Wall St. Rank hold DNLI as of Q2 2024.

Flagship Pioneering reported no remaining Denali Therapeutics position as of Q2 2024 after selling out during the quarter.
Flagship Pioneering sold 1,364,516 Denali Therapeutics shares in Q2 2024, an estimated $28M.
Flagship Pioneering first reported a position in Denali Therapeutics in Q4 2017 and held it in 26 quarters.
Flagship Pioneering's Denali Therapeutics position peaked at $229M in Q4 2020.
203 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2024.

Based on Flagship Pioneering's 13F filing for Q2 2024, filed 14 Aug 2024.